Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prostate-specific Membrane Antigen Positive Tumors”

57 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 57 results

Not applicableStudy completedNCT02978586
What this trial is testing

A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors

Who this might be right for
Prostate-specific Membrane Antigen Positive TumorsProstate CancerBreast Cancer+1 more
Case Comprehensive Cancer Center 8
Early research (Phase 1)Active Not RecruitingNCT07236112
What this trial is testing

Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer

Who this might be right for
Prostate Cancer
C Ray Therapeutics 6
Testing effectiveness (Phase 2)Study completedNCT05670106
What this trial is testing

Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 62
Very early researchStudy completedNCT06359821
What this trial is testing

Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
Sichuan University 4
Not applicableStudy completedNCT06809426
What this trial is testing

Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer

Who this might be right for
PSMA PET-Positive Castration-Resistant Prostate Cancer
Affiliated Hospital of Jiangnan University 13
Testing effectiveness (Phase 2)WithdrawnNCT02876003
What this trial is testing

Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma

Who this might be right for
Glioblastoma
GenSpera, Inc.
Large-scale testing (Phase 3)Not Yet RecruitingNCT07795268
What this trial is testing

Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer
Norroy Bioscience Co., LTD 600
Large-scale testing (Phase 3)Study completedNCT04838626
What this trial is testing

Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection

Who this might be right for
Prostatic NeoplasmsProstate Cancer
Novartis Pharmaceuticals 195
Testing effectiveness (Phase 2)Study completedNCT05114746
What this trial is testing

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 94
Not applicableTemporarily Not AvailableNCT06033001
What this trial is testing

Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Castration-Resistant Prostatic Cancer
Lantheus Medical Imaging
Large-scale testing (Phase 3)Looking for participantsNCT07426094
What this trial is testing

PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer

Who this might be right for
Prostate CancerBrachytherapyStereotactic Body Radiation Therapy (SBRT)+2 more
Affidea Nu-med Center of Oncological DIagnostics and Therapy 600
Testing effectiveness (Phase 2)Ended earlyNCT06322576
What this trial is testing

177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

Who this might be right for
Adenoid Cystic Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT06383052
What this trial is testing

177Lu-NYM032 Injection in mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Norroy Bioscience Co., LTD 30
Large-scale testing (Phase 3)Looking for participantsNCT06855277
What this trial is testing

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 940
Early research (Phase 1)Ended earlyNCT03490838
What this trial is testing

177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasm
Advanced Accelerator Applications 27
Not applicableUnknownNCT06201741
What this trial is testing

Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled ZT-111 in Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Specific Membrane Antigen Positive Metastatic Prostate Cancer
Huashan Hospital 10
Testing effectiveness (Phase 2)Looking for participantsNCT07226986
What this trial is testing

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Who this might be right for
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals 123
Not applicableLooking for participantsNCT06850545
What this trial is testing

Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate AdenocarcinomaPSMA PET-Positive Castration-Resistant Prostate Cancer
Kuopio University Hospital 150
Large-scale testing (Phase 3)Study completedNCT03511664
What this trial is testing

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Endocyte 861
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07310355
What this trial is testing

68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Chengdu StarRay Therapeutics Co., Ltd 49
Next Page